Literature DB >> 28039413

URAT1 inhibition by ALPK1 is associated with uric acid homeostasis.

Tzer-Min Kuo1, Chung-Ming Huang2, Hung-Pin Tu3, Albert Min-Shan Ko4, Shu-Jung Wang5, Chi-Pin Lee5, Ying-Chin Ko1,6.   

Abstract

Objective: The aim of this study was to identify a protein for urate transporter 1 (URAT1) regulation.
Methods: The clinical dataset consisted of 492 case-control samples of Han Chinese (104 gout and 388 controls). Three alpha kinase 1 ( ALPK1 ) and SLC22A12 loci associated with high gout risk and uric acid levels were genotyped. The overexpression of ALPK1 on URAT1 protein expression was evaluated in vivo in h ALPK1 transgenic mice. The in vitro protein levels of ALPK1 and URAT1 in ALPK1 small interfering RNA-transfected human kidney-2 cells with MSU crystal stimulation were examined.
Results: ALPK1 , which is a single nucleotide polymorphism (SNP) of rs11726117 (M861T; T), reduced the risk of gout via the SLC22A12 gene SNPs rs3825016 and rs475688, as compared with the subject of ALPK1 rs11726117 (C) allele {rs11726117 [CT + TT] vs rs3825016, odds ratio [OR] 0.39 [95% confidence interval (CI) 0.23, 0.67]; rs11726117 [CT + TT] vs rs475688, OR 0.39 [95% CI 0.23, 0.67]}. ALPK1-overexpressed mice demonstrated lower levels of URAT1 protein ( P = 0.0045). Mouse endogenous ALPK1 proteins were detected in renal proximal tubule cells. MSU crystals inhibited URAT1 expressions through an upregulation of ALPK1 in human kidney-2 cells.
Conclusion: Elevated ALPK1 expression decreased URAT1 expression. ALPK1 might prevent the impact of urate reuptake via SLC22A12 and appeared to be negatively associated with gout. ALPK1 is a potential repressor of URAT1 protein expression.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  ALPK1; MSU; URAT1; gout; hyperuricaemia

Mesh:

Substances:

Year:  2017        PMID: 28039413     DOI: 10.1093/rheumatology/kew463

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

1.  Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout.

Authors:  Hung-Pin Tu; Albert Min-Shan Ko; Su-Shin Lee; Chi-Pin Lee; Tzer-Min Kuo; Chung-Ming Huang; Ying-Chin Ko
Journal:  J Hum Genet       Date:  2017-11-08       Impact factor: 3.172

2.  Differential gene expression of ABCG2, SLC22A12, IL-1β, and ALPK1 in peripheral blood leukocytes of primary gout patients with hyperuricemia and their comorbidities: a case-control study.

Authors:  Paniagua-Díaz Natsuko; Sanchez-Chapul Laura; Clavijo-Cornejo Denise; Ventura-Ríos Lucio; Aguilar-Salinas Carlos; Sanchez-Muñoz Fausto; López-Macay Ambar
Journal:  Eur J Med Res       Date:  2022-05-03       Impact factor: 4.981

3.  Effects of uric acid dysregulation on the kidney.

Authors:  Lashodya V Dissanayake; Denisha R Spires; Oleg Palygin; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-30

4.  ALPK1 regulates streptozotocin-induced nephropathy through CCL2 and CCL5 expressions.

Authors:  Chi-Pin Lee; Srinivasan Nithiyanantham; Hui-Ting Hsu; Kun-Tu Yeh; Tzer-Min Kuo; Ying-Chin Ko
Journal:  J Cell Mol Med       Date:  2019-09-26       Impact factor: 5.310

Review 5.  Research progress of risk factors and early diagnostic biomarkers of gout-induced renal injury.

Authors:  Sheng Wang; Liyun Zhang; Dongsheng Hao; Lei Wang; Jiaxi Liu; Qing Niu; Liangyu Mi; Xinyue Peng; Jinfang Gao
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

6.  Alpha kinase 1 controls intestinal inflammation by suppressing the IL-12/Th1 axis.

Authors:  Grigory Ryzhakov; Nathaniel R West; Fanny Franchini; Simon Clare; Nicholas E Ilott; Stephen N Sansom; Samuel J Bullers; Claire Pearson; Alice Costain; Alun Vaughan-Jackson; Jeremy A Goettel; Joerg Ermann; Bruce H Horwitz; Ludovico Buti; Xin Lu; Subhankar Mukhopadhyay; Scott B Snapper; Fiona Powrie
Journal:  Nat Commun       Date:  2018-09-18       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.